1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics
(
- Contribution to journal › Article
-
Mark
Intratumoral Distribution of [177Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer
2024) In Cancer Biotherapy and Radiopharmaceuticals(
- Contribution to journal › Article
- 2023
-
Mark
Single-cell quantification and dose-response of cytosolic siRNA delivery
(
- Contribution to journal › Article
-
Mark
Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer
(
- Contribution to journal › Article
-
Mark
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
(
- Contribution to journal › Article
- 2021
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article